A Phase 2, Open Label Study to Evaluate Safety and Clinical Activity of Avelumab (BAVENCIO®) in Combination With Axitinib (INLYTA®) in Patients With Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naïve Cisplatin-Ineligible Urothelial Cancer (JAVELIN Medley VEGF)